Lineage Cell Therapeutics, Inc. (LCTX) earnings date, results and what the price requires
NYSE · SEC CIK 0000876343 · SEC filings checked Oct 16, 2026
Next report
Oct 30, 2026
Estimated from reporting history (86-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$0.98
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$-0.19
Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $1.1M | $1.5M | $-0.03 | Filing |
| Mar 31, 2026 | May 12, 2026 | $1.7M | $-4.8M | $-0.03 | Filing |
| Dec 31, 2025 | Mar 5, 2026 | $6.6M | $851,000 | $0.00 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $3.7M | $-29.8M | $-0.13 | Filing |
| Jun 30, 2025 | Aug 12, 2025 | $2.8M | $-30.5M | $-0.13 | Filing |
| Mar 31, 2025 | May 13, 2025 | $1.5M | $-4.1M | $-0.02 | Filing |
| Dec 31, 2024 | Mar 10, 2025 | $2.9M | $-3.3M | $0.00 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | $3.8M | $-3.0M | $-0.02 | Filing |
What would Lineage Cell Therapeutics, Inc. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.